Plus Therapeutics (PSTV)
NASDAQ:PSTV
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$0.16 - $1.77
Previous CloseN/A
Volume69.06K
Average Volume (3M)4.20M
Market Cap
$41.67M
Enterprise Value$6.76M
Total Cash (Recent Filing)$8.76M
Total Debt (Recent Filing)$821.00K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Apr 16, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding171,550,700
10 Day Avg. Volume3,673,493
30 Day Avg. Volume4,203,915
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)99.75
Price to Sales (P/S)76.46
P/FCF Ratio-19.12
Enterprise Value/Market Cap0.16
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit1.42
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$1.50Price Target Upside158.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$6.23M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsEarlier trial data suggesting longer survival and acceptable tolerability for the radiotherapeutic strengthen the clinical case for further development in glioblastoma and may aid enrollment and investor confidence.
Diagnostic Platform ExpansionPlans to add next-generation sequencing and fluorescence in-situ hybridization to the CNSide platform should expand clinical utility and create additional avenues for diagnostic revenue.
Reimbursement And Payer CoverageNational coverage agreements with major insurers substantially broaden patient access to the CNSide test, supporting higher test volumes and accelerating clinical adoption.
Bears Say
Clinical Endpoint UncertaintyFDA indication that circulating tumor cells may not suffice as a primary surrogate endpoint increases reliance on overall survival and quality-of-life measures, raising trial complexity and the bar for approval.
Equity Dilution RiskCompletion of a public equity offering increased dilution risk and could exert downward pressure on the share price as ownership stakes are spread among more shareholders.
Operational And Legal RisksValuation and outlook remain vulnerable to potential clinical setbacks, commercial challenges, partnership disruptions, financial constraints, and intellectual property disputes that could undermine growth expectations.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $0.16 and its highest was $1.77 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $41.67M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Apr 16, 2026 which is in 20 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.033 earnings per share for the quarter, missing the consensus estimate of -$0.032 by -$0.001.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.03.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 171,550,700 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$0.033 in its last earnings report, missing expectations of -$0.032. Following the earnings report the stock price went down -14.966%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.50 (158.62% Upside)
$1.50 (158.62% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.86%
12-Months-Change
Fundamentals
Return on Equity
774.80%
Trailing 12-Months
Asset Growth
146.12%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Stock 12 Month Forecast
Average Price Target
$1.50
▲(158.62% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
0.37% Insiders
1.37% Mutual Funds
1.40% Other Institutional Investors
95.99% Public Companies and Individual Investors
Options Prices
Currently, No data available
---